| Literature DB >> 21742494 |
Richard T Carroll1, Dean E Dluzen, Hilary Stinnett, Prabha S Awale, Max O Funk, Werner J Geldenhuys.
Abstract
The neuroprotective activity of pioglitazone and rosiglitazone in the MPTP parkinsonian mouse prompted us to evaluate a set of thiazolidinedione (TZD) type compounds for monoamine oxidase A and B inhibition activity. These compounds were able to inhibit MAO-B over several log units of magnitude (82 nM to 600 μM). Initial structure-activity relationship studies identified key areas to modify the aromatic substituted TZD compounds. Primarily, substitutions on the aromatic group and the TZD nitrogen were key areas where activity was enhanced within this group of compounds.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21742494 DOI： 10.1016/j.bmcl.2011.06.060
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823